{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:17:41Z","timestamp":1790713061342,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis B virus\u00a0(HBV) is a global health threat, and its elimination by 2030 has been prioritised by the World Health Organisation. Here we present an age-structured model for the immune response to an HBV infection, which takes into account contributions from both cell-mediated and humoral immunity. The model has been validated using published patient data recorded during acute infection. It has been adapted to the scenarios of chronic infection, clearance of infection, and flare-ups via variation of the immune response parameters. The impacts of immune response exhaustion and non-infectious subviral particles on the immune response dynamics are analysed. A comparison of different treatment options in the context of this model reveals that drugs targeting aspects of the viral life cycle are more effective than exhaustion therapy, a form of therapy mitigating immune response exhaustion. Our results suggest that antiviral treatment is best started when viral load is declining rather than in a flare-up. The model suggests that a fast antibody production rate always leads to viral clearance, highlighting the promise of antibody therapies currently in clinical trials.<\/jats:p>","DOI":"10.1038\/s41598-021-04022-z","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T11:03:57Z","timestamp":1643022237000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["An age-structured model of hepatitis B viral infection highlights the potential of different therapeutic strategies"],"prefix":"10.1038","volume":"12","author":[{"given":"Farzad","family":"Fatehi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Bingham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Stockley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reidun","family":"Twarock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"4022_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/jmv.1890080404","volume":"8","author":"P Mackay","year":"1981","unstructured":"Mackay, P., Lees, J. & Murray, K. The conversion of hepatitis B core antigen synthesized in E coli into e antigen. J. Med. Virol. 8, 237\u2013243 (1981).","journal-title":"J. Med. Virol."},{"key":"4022_CR2","doi-asserted-by":"crossref","unstructured":"Murray, K., Stahl, S. & Ashton-Rickardt, P.\u00a0G. Genetic engineering applied to the development of vaccines. Philos. Trans. R. Soc. Lond. B Biol. Sci. 324, 461\u2013476 (1989).","DOI":"10.1098\/rstb.1989.0060"},{"key":"4022_CR3","unstructured":"WHO. Global Hepatitis Report (World Health Organization, 2021)."},{"key":"4022_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/v9030056","volume":"9","author":"J Hu","year":"2017","unstructured":"Hu, J. & Liu, K. Complete and incomplete hepatitis B virus particles: formation, function, and application. Viruses 9, 56 (2017).","journal-title":"Viruses"},{"key":"4022_CR5","doi-asserted-by":"crossref","unstructured":"Ciupe, S. M., Ribeiro, R. M. & Perelson, A. S. Antibody responses during hepatitis B viral infection. PLoS Comput. Biol. 10, e1003730 (2014).","DOI":"10.1371\/journal.pcbi.1003730"},{"key":"4022_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.284.5415.825","volume":"284","author":"LG Guidotti","year":"1999","unstructured":"Guidotti, L. G. et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 825\u2013829 (1999).","journal-title":"Science"},{"key":"4022_CR7","volume-title":"Cellular and molecular immunology","author":"AK Abbas","year":"2014","unstructured":"Abbas, A. K., Lichtman, A. H. & Pillai, S. Cellular and molecular immunology (Elsevier, Philadelphia, US, 2014)."},{"key":"4022_CR8","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.1073\/pnas.0603626104","volume":"104","author":"SM Ciupe","year":"2007","unstructured":"Ciupe, S. M., Ribeiro, R. M., Nelson, P. W., Dusheiko, G. & Perelson, A. S. The role of cells refractory to productive infection in acute hepatitis B viral dynamics. Proc. Natl. Acad. Sci. USA 104, 5050\u20135055 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4022_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jtbi.2007.02.017","volume":"247","author":"SM Ciupe","year":"2007","unstructured":"Ciupe, S. M., Ribeiro, R. M., Nelson, P. W. & Perelson, A. S. Modeling the mechanisms of acute hepatitis B virus infection. J. Theor. Biol. 247, 23\u201335 (2007).","journal-title":"J. Theor. Biol."},{"key":"4022_CR10","doi-asserted-by":"crossref","unstructured":"Fatehi\u00a0Chenar, F., Kyrychko, Y.\u00a0N. & Blyuss, K.\u00a0B. Mathematical model of immune response to hepatitis B. J. Theor. Biol. 447, 98\u2013110 (2018).","DOI":"10.1016\/j.jtbi.2018.03.025"},{"key":"4022_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3934\/mbe.2004.1.267","volume":"1","author":"PW Nelson","year":"2004","unstructured":"Nelson, P. W., Gilchrist, M. A., Coombs, D., Hyman, J. M. & Perelson, A. S. An age-structured model of HIV infection that allows for variations in the production rate of viral particles and the death rate of productively infected cells. Math. Biosci. Eng. 1, 267\u2013288 (2004).","journal-title":"Math. Biosci. Eng."},{"key":"4022_CR12","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3934\/mbe.2016022","volume":"13","author":"C Browne","year":"2016","unstructured":"Browne, C. Immune response in virus model structured by cell infection-age. Math. Biosci. Eng. 13, 887 (2016).","journal-title":"Math. Biosci. Eng."},{"key":"4022_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/362758a0","volume":"362","author":"D Moskophidis","year":"1993","unstructured":"Moskophidis, D., Lechner, F., Pircher, H. & Zinkernagel, R. M. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 362, 758\u2013761 (1993).","journal-title":"Nature"},{"key":"4022_CR14","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1084\/jem.188.12.2205","volume":"188","author":"AJ Zajac","year":"1998","unstructured":"Zajac, A. J. et al. Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188, 2205\u20132213 (1998).","journal-title":"J. Exp. Med."},{"key":"4022_CR15","doi-asserted-by":"publisher","first-page":"5535","DOI":"10.1128\/JVI.78.11.5535-5545.2004","volume":"78","author":"EJ Wherry","year":"2004","unstructured":"Wherry, E. J. & Ahmed, R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78, 5535\u20135545 (2004).","journal-title":"J. Virol."},{"key":"4022_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545\u2013558 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"4022_CR17","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1128\/JVI.00166-11","volume":"85","author":"PLF Johnson","year":"2011","unstructured":"Johnson, P. L. F. et al. Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections. J. Virol. 85, 5565\u20135570 (2011).","journal-title":"J. Virol."},{"key":"4022_CR18","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.1073\/pnas.1419162112","volume":"112","author":"JM Conway","year":"2015","unstructured":"Conway, J. M. & Perelson, A. S. Post-treatment control of HIV infection. Proc. Natl. Acad. Sci. USA 112, 5467\u20135472 (2015).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4022_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/v13010011","volume":"13","author":"F Fatehi","year":"2021","unstructured":"Fatehi, F. et al. An intracellular model of hepatitis B viral infection: an in silico platform for comparing therapeutic strategies. Viruses 13, 11 (2021).","journal-title":"Viruses"},{"key":"4022_CR20","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1073\/pnas.1203110110","volume":"110","author":"J Guedj","year":"2013","unstructured":"Guedj, J. et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life. Proc. Natl. Acad. Sci. USA 110, 3991\u20133996 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4022_CR21","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.3934\/mbe.2019279","volume":"16","author":"F Fatehi","year":"2019","unstructured":"Fatehi, F., Kyrychko, Y. N. & Blyuss, K. B. Time-delayed model of autoimmune dynamics. Math. Biosci. Eng. 16, 5613\u20135639 (2019).","journal-title":"Math. Biosci. Eng."},{"key":"4022_CR22","unstructured":"Jagadish, B. Mathematical Modeling of T-cell Exhaustion and PD-1 Blockade in Chronic Infections. Master\u2019s thesis, University of California Irvine, the USA (2015)."},{"key":"4022_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3390\/v9110350","volume":"9","author":"A Goyal","year":"2017","unstructured":"Goyal, A., Ribeiro, R. M. & Perelson, A. S. The role of infected cell proliferation in the clearance of acute HBV infection in humans. Viruses 9, 350 (2017).","journal-title":"Viruses"},{"key":"4022_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jtbi.2014.11.020","volume":"366","author":"JM Murray","year":"2015","unstructured":"Murray, J. M. & Goyal, A. In silico single cell dynamics of hepatitis B virus infection and clearance. J. Theor. Biol. 366, 91\u2013102 (2015).","journal-title":"J. Theor. Biol."},{"key":"4022_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jtbi.2018.04.006","volume":"448","author":"K Kitagawa","year":"2018","unstructured":"Kitagawa, K., Nakaoka, S., Asai, Y., Watashi, K. & Iwami, S. A PDE multiscale model of hepatitis C virus infection can be transformed to a system of ODEs. J. Theor. Biol. 448, 80\u201385 (2018).","journal-title":"J. Theor. Biol."},{"key":"4022_CR26","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12879-019-3813-x","volume":"19","author":"Y Guang","year":"2019","unstructured":"Guang, Y., Yuzhong, L. & Hui, L. Establishment of an analysis model based on measurement of hepatitis B viral infection serum markers. BMC Infect. Dis. 19, 171 (2019).","journal-title":"BMC Infect. Dis."},{"key":"4022_CR27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1073\/pnas.0308478100","volume":"101","author":"SF Wieland","year":"2004","unstructured":"Wieland, S. F., Spangenberg, H. C., Thimme, R., Purcell, R. H. & Chisari, F. V. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc. Natl. Acad. Sci. USA 101, 2129\u20132134 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4022_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1053\/jhep.2000.19324","volume":"32","author":"GJM Webster","year":"2000","unstructured":"Webster, G. J. M. et al. Incubation phase of acute hepatitis B in man: Dynamic of cellular immune mechanisms. Hepatology 32, 1117\u20131124 (2000).","journal-title":"Hepatology"},{"key":"4022_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1086\/314578","volume":"179","author":"AD Jack","year":"1999","unstructured":"Jack, A. D., Hall, A. J., Maine, N., Mendy, M. & Whittle, H. C. What level of hepatitis B antibody is protective?. J. Infect. Dis. 179, 489\u2013492 (1999).","journal-title":"J. Infect. Dis."},{"key":"4022_CR30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jhep.2014.08.033","volume":"61","author":"M-L Chang","year":"2014","unstructured":"Chang, M.-L. & Liaw, Y.-F. Hepatitis B flares in chronic hepatitis B: Pathogenesis, natural course, and management. J. Hepatol. 61, 1407\u20131417 (2014).","journal-title":"J. Hepatol."},{"key":"4022_CR31","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1053\/gast.2001.22461","volume":"120","author":"RP Perrillo","year":"2001","unstructured":"Perrillo, R. P. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120, 1009\u20131022 (2001).","journal-title":"Gastroenterology"},{"key":"4022_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jhep.2017.05.008","volume":"67","author":"AS Lok","year":"2017","unstructured":"Lok, A. S., Zoulim, F., Dusheiko, G. & Ghany, M. G. Hepatitis B cure: From discovery to regulatory approval. J. Hepatol. 67, 847\u2013861 (2017).","journal-title":"J. Hepatol."},{"key":"4022_CR33","doi-asserted-by":"publisher","first-page":"8138","DOI":"10.1073\/pnas.0409732102","volume":"102","author":"SJ Stray","year":"2005","unstructured":"Stray, S. J. et al. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc. Natl. Acad. Sci. USA 102, 8138\u20138143 (2005).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4022_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep22952","volume":"6","author":"H Stewart","year":"2016","unstructured":"Stewart, H. et al. Identification of novel RNA secondary structures within the hepatitis C virus genome reveals a cooperative involvement in genome packaging. Sci. Rep. 6, 1\u201312 (2016).","journal-title":"Sci. Rep."},{"key":"4022_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nmicrobiol.2017.98","volume":"2","author":"N Patel","year":"2017","unstructured":"Patel, N. et al. HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly. Nat. Microbiol. 2, 1\u201310 (2017).","journal-title":"Nat. Microbiol."},{"key":"4022_CR36","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev-biophys-052118-115611","volume":"48","author":"R Twarock","year":"2019","unstructured":"Twarock, R. & Stockley, P. G. RNA-mediated virus assembly: Mechanisms and consequences for viral evolution and therapy. Ann. Rev. Biophys. 48, 495\u2013514 (2019).","journal-title":"Ann. Rev. Biophys."},{"key":"4022_CR37","first-page":"1263A","volume":"66","author":"F Zoulim","year":"2017","unstructured":"Zoulim, F. et al. Safety, tolerability, pharmacokinetics and antiviral activity of JNJ-56136379, a novel HBV capsid assembly modulator, in non-cirrhotic, treatment-naive subjects with chronic hepatitis B. In Hepatology 66, 1263A-1264A (2017).","journal-title":"In Hepatology"},{"key":"4022_CR38","doi-asserted-by":"publisher","first-page":"e00835","DOI":"10.1128\/AAC.00835-18","volume":"62","author":"T Lahlali","year":"2018","unstructured":"Lahlali, T. et al. Novel potent capsid assembly modulators regulate multiple steps of the hepatitis B virus life cycle. Antimicrob. Agents Chemother. 62, e00835-18 (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"4022_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1053\/j.gastro.2020.04.036","volume":"159","author":"F Zoulim","year":"2020","unstructured":"Zoulim, F. et al. JNJ-56136379, an HBV capsid assembly modulator, is well-tolerated and has antiviral activity in a phase 1 study of patients with chronic infection. Gastroenterology 159, 521\u2013533 (2020).","journal-title":"Gastroenterology"},{"key":"4022_CR40","doi-asserted-by":"crossref","unstructured":"Reinharz, V. et al. Understanding hepatitis B virus dynamics and the antiviral effect of interferon-$$\\alpha$$ treatment in humanized chimeric mice. J. Virol. 95, e0049220 (2021).","DOI":"10.1128\/JVI.00492-20"},{"key":"4022_CR41","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/1741-7007-11-96","volume":"11","author":"AS Perelson","year":"2013","unstructured":"Perelson, A. S. & Ribeiro, R. M. Modeling the within-host dynamics of HIV infection. BMC Biol. 11, 96 (2013).","journal-title":"BMC Biol."},{"key":"4022_CR42","doi-asserted-by":"crossref","unstructured":"Czuppon, P. et al. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. PLoS Comput. Biol. 17, e1008752 (2021).","DOI":"10.1371\/journal.pcbi.1008752"},{"key":"4022_CR43","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/psp4.12543","volume":"9","author":"A Gon\u00e7alves","year":"2020","unstructured":"Gon\u00e7alves, A. et al. Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. CPT Pharmacomet. Syst. Pharmacol. 9, 509\u2013514 (2020).","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"4022_CR44","doi-asserted-by":"crossref","unstructured":"Iwanami, S. et al. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med. 18, e1003660 (2021).","DOI":"10.1371\/journal.pmed.1003660"},{"key":"4022_CR45","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/cpt.2160","volume":"109","author":"AS Perelson","year":"2021","unstructured":"Perelson, A. S. & Ke, R. Mechanistic modeling of SARS-CoV-2 and other infectious diseases and the effects of therapeutics. Clin. Pharmacol. Ther. 109, 829\u2013840 (2021).","journal-title":"Clin. Pharmacol. Ther."},{"key":"4022_CR46","doi-asserted-by":"crossref","unstructured":"Guo, F. et al. HBV core protein allosteric modulators differentially alter cccDNA biosynthesis from de novo infection and intracellular amplification pathways. PLoS Pathog. 13, e1006658 (2017).","DOI":"10.1371\/journal.ppat.1006658"},{"key":"4022_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.22586","volume":"49","author":"H Dahari","year":"2009","unstructured":"Dahari, H., Shudo, E., Ribeiro, R. M. & Perelson, A. S. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 49, 32\u201338 (2009).","journal-title":"Hepatology"},{"key":"4022_CR48","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1080\/21645515.2017.1319021","volume":"13","author":"Y Gao","year":"2017","unstructured":"Gao, Y., Zhang, T.-Y., Yuan, Q. & Xia, N.-S. Antibody-mediated immunotherapy against chronic hepatitis B virus infection. Hum. Vaccin. Immunother. 13, 1768\u20131773 (2017).","journal-title":"Hum. Vaccin. Immunother."},{"key":"4022_CR49","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.3389\/fimmu.2019.02290","volume":"10","author":"A Cerino","year":"2019","unstructured":"Cerino, A. et al. Human monoclonal antibodies as adjuvant treatment of chronic hepatitis B virus infection. Front. Immunol. 10, 2290 (2019).","journal-title":"Front. Immunol."},{"key":"4022_CR50","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.3390\/jcm9103187","volume":"9","author":"A Alexopoulou","year":"2020","unstructured":"Alexopoulou, A., Vasilieva, L. & Karayiannis, P. New approaches to the treatment of chronic hepatitis B. J. Clin. Med. 9, 3187 (2020).","journal-title":"J. Clin. Med."},{"key":"4022_CR51","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1053\/j.gastro.2017.08.034","volume":"153","author":"M Duss\u00e9aux","year":"2017","unstructured":"Duss\u00e9aux, M. et al. Viral load affects the immune response to HBV in mice with humanized immune system and liver. Gastroenterology 153, 1647\u20131661 (2017).","journal-title":"Gastroenterology"},{"key":"4022_CR52","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/s41592-018-0071-6","volume":"15","author":"Y Li","year":"2018","unstructured":"Li, Y. et al. A human immune system mouse model with robust lymph node development. Nat. Methods 15, 623\u2013630 (2018).","journal-title":"Nat. Methods"},{"key":"4022_CR53","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1084\/jem.193.7.847","volume":"193","author":"SA Whalley","year":"2001","unstructured":"Whalley, S. A. et al. Kinetics of acute hepatitis B virus infection in humans. J. Exp. Med. 193, 847\u2013854 (2001).","journal-title":"J. Exp. Med."},{"key":"4022_CR54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/jcp.21172","volume":"213","author":"GK Michalopoulos","year":"2007","unstructured":"Michalopoulos, G. K. Liver regeneration. J. Cell. Physiol. 213, 286\u2013300 (2007).","journal-title":"J. Cell. Physiol."},{"key":"4022_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-56553-3_1","volume":"161","author":"Z Kmiec","year":"2001","unstructured":"Kmiec, Z. Cooperation of liver cells in health and disease. Adv. Anat. Embryol. Cell Biol. 161, 1\u2013151 (2001).","journal-title":"Adv. Anat. Embryol. Cell Biol."},{"key":"4022_CR56","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.apnum.2005.04.027","volume":"56","author":"S Thompson","year":"2006","unstructured":"Thompson, S. & Shampine, L. F. A friendly fortran DDE solver. Appl. Numer. Math. 56, 503\u2013516 (2006).","journal-title":"Appl. Numer. Math."},{"key":"4022_CR57","first-page":"338","volume":"20","author":"R O\u2019Neill","year":"1971","unstructured":"O\u2019Neill, R. Algorithm AS 47: Function minimization using a simplex procedure. J. R. Stat. Soc. C-Appl. 20, 338\u2013345 (1971).","journal-title":"J. R. Stat. Soc. C-Appl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04022-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04022-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:08:50Z","timestamp":1669324130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04022-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4022"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04022-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"7 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1252"}}